New research led by the University of Portsmouth has revealed how Duchenne muscular dystrophy (DMD), best known for causing ...
WVE-N531 demonstrated statistically significant improvements in muscle biopsy measures and functional measures in patients ...
Clinical Trials Arena on MSN1d
Wave Life Sciences unveils Phase II data for DMD therapy, WVE-N531Wave Life Sciences’ Phase II open-label trial investigating its disease-modifying drug for boys living with Duchenne Muscular ...
Born with Duchenne muscular dystrophy and diagnosed at 4 months old in 1996, he is currently based in the Eastern part of Singapore. His hope for his column is to advocate for the health and ...
For millions of people, losing muscle isn't just about weakness; it's about losing independence. Whether caused by Duchenne muscular dystrophy, aging or other degenerative conditions, muscle loss can ...
Delandistrogene moxeparvovec, a gene therapy approved for the treatment of Duchenne muscular dystrophy (DMD), was found ...
The Cambridge-based biotech's experimental treatment for Duchenne muscular dystrophy hit the mark in a mid-stage study, ...
Clinical Trials Arena on MSN1d
Duchenne muscular dystrophy: Five trials to watchAmid readouts from the Muscular Dystrophy Association’s annual meeting, the Clinical Trials Arena evaluates five DMD trials to keep an eye on in 2025.
The company plans to file next year for an accelerated clearance of its "exon-skipping" treatment, which would compete with one of Sarepta's medicines.
Wave Life Sciences reports positive Phase 2 results for DMD drug WVE-N531, with 7.8% dystrophin expression at 24-48 weeks, ...
The firm will seek accelerated approval for WVE-N531 in DMD amenable to exon 53 skipping based on FDA feedback and Phase II data.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback